. In fact, the development of computational tools that can analyse increasingly large single-cell datasets is lagging behind the advances in experimental methods.
. This landscape is rapidly changing, and several technologies that can comprehensively analyse the single cell at the molecular level have now emerged. For example, some single-cell tools and methods can assay reasonably large numbers (>40) of secreted proteins 8 , equally large numbers of cell surface markers 9 and elements of phosphoprotein signalling pathways 10, 11 . In addition, single cells can now be analysed for the genome at focused 12, 13 or high coverage 14 , the transcriptome at sparse coverage 15, 16 or the entire transcriptome with moderate 17 or high 18 cell statistics. Additional reports in which integrated measurements of genes and transcripts 19 , limited numbers of proteins, transcripts 20, 21 and genes 22 , and panels of proteins and metabolites 23 from single cells have also appeared. Microfluidics methods permit molecular analysis to be correlated with measurements of specific cellular functions (such as motility) or enable the analysis of defined, small populations of cells (that is, two to three cells) [24] [25] [26] . Microfluidic designs can also permit cell analysis within highly controlled, custom environments [27] [28] [29] , or can allow for non-destructive cell analysis so that cells identified as interesting, such as B cells producing specific antibodies, can be harvested for further use 30, 31 . Two recent tissue staining methods, in situ RNA profiling via sequential hybridization [32] [33] [34] and proteomic analysis via ion beam profiling 35 , enable the analysis of single cells within fixed, intact tissues, with a level of multiplexing that significantly exceeds traditional immunohistochemical staining methods. The level of analyte quantification varies from measurements that yield copy numbers per cell 18, 32, 36 to relative quantification between cells. Many of these methods generate relatively new types of data and are therefore being integrated with new computational approaches [37] [38] [39] [40] [41] . In fact, the development of computational tools that can analyse increasingly large single-cell datasets is lagging behind the advances in experimental methods.
Although these diverse and rapidly evolving singlecell technologies provide remarkable opportunities for drug discovery and development, they also provide a deluge of information for the non-technologist. This Review is therefore intended to serve as a guide for the non-specialist. Here, we describe the state of the art of single-cell biology tools for different analyte classes and discuss the new types of biological information that can be gleaned through the use of these tools, highlighted using three examples. To illustrate the broader application of these emerging technologies, these tools are placed within the context of two classes of cancer therapies. The first is the development and use of targeted inhibitors for treating heterogeneous tumours. The second is cancer immunotherapy, which is an area in which several single-cell analysis tools are already having important roles.
Single-cell analysis tools can be grouped according to the measured analytes, that is, genomics-, transcriptomics-, proteomics-or metabolomics-based approaches, or by a combination of these. It is anticipated that the methods described here are likely to emerge in the marketplace
Whole-genome amplification
A method, first reported using PCR by Arnheim's group, for nonselectively amplifying all DNA sequences present in a given sample, including a single cell.
Multiple displacement amplification
A non-PCR based, room temperature DNA amplification technique reported by Lasken's group that is commonly used for whole-genome amplification.
Multiple annealing and looping-based amplification cycles (MALBAC) . A PCR-type approach reported by Xie's group in which the enzymatic amplification of cDNAs proceeds via a linear process.
Exome sequencing
Genome sequencing that is limited to only the small fraction (1%) of the genome that is protein encoding.
RNA-sequencing
(RNA-seq). Also called whole transcriptome shotgun sequencing, RNA-seq is a method for analysing the transcriptome of a sample using next-generation sequencing tools.
Molecular barcoding
An approach through which a DNA sequence or some other molecular identifier is used as an identifier of a specific cell or a specific transcript generated by that cell. Unique molecular index (UMI) . A molecular barcode used to identify a specific transcript from a specific cell.
DropSeq
A nanodrop-based single-cell transcriptomics method reported by Macosko and others in 2015.
within a couple of years, although earlier generation variants are, in many cases, already commercially available as whole platforms, commercial services or through the purchase of essential reagents.
Single-cell analysis tools Below, we review the state of the art in analytical tools designed for single-cell genomics, transcriptomics and proteomics, with a particular emphasis on quantitative, highly multiplex assays that can perform measurements on many single cells in a given experimental run. Many of the reviewed methods are very new.
Single-cell genomics. The rapid technological advances in DNA sequencing tools have exposed the whole genome, the exome and the transcriptome for single-cell analysis. For single-cell whole-genome sequencing 12, 42, 43 , the genome must be amplified before sequencing. In principle, amplification can be performed with PCR-based whole-genome amplification methods 44 , but such methods are prone to bias because random genes can be overor under-amplified by the nonlinear PCR process 45 . A commonly used alternative is the multiple displacement amplification method, which is a technique that utilizes the φ29 DNA polymerase enzyme for DNA synthesis 46 , and can amplify DNA isothermally at 30 o C. Multiple displacement amplification provides an improved representation of the entire genome, but the φ29 enzyme is still a nonlinear amplifier (similar to PCR), and can therefore yield bias. Such bias in turn makes it difficult to discern copy number variations and single-nucleotide variations, although Dago and co-workers have reported measurements of such quantities from single circulating tumour cells (CTCs) originating from prostate cancer 47 . A second whole-genome amplification approach, called multiple annealing and looping-based amplification cycles (MALBAC), has been recently reported 48 . MALBAC is designed so that the initial polymerase amplification steps yield an amplicon that cyclizes due to complementary sequences incorporated into the 3ʹ and 5ʹ ends, which makes the amplicon unavailable as a template. The cyclization of the amplicon keeps the initial genome amplification process linear and reduces amplification bias. As a result, copy number variations and single-nucleotide variations can be reliably quantitated at the single-cell level. As an illustrative example, MALBAC has been extended to the analysis of CTCs from patients with lung cancer 49 . For certain challenging genes, such as oncogenes with multiple variants 50 or the T cell receptor-α (TCRα) and TCRβ genes (TCRA and TCRB, respectively), nested PCR methods 51, 52 coupled with Sanger sequencing are used. Recent, highly parallel, multi-step RT-PCR-based techniques, coupled with next-generation sequencing tools, now allow such sequences to be determined from many (100 or more) single cells in parallel 53 . Various target-enrichment strategies have been developed to broadly select genomic regions of interest for sequencing 54 . For example, as methods for exome sequencing have become standardized 55, 56 , they have been extended to single-cell analysis 57 . Exome sequencing is a relatively cost-effective procedure that yields an enriched dataset of highly penetrant variants, such as those that are relevant to genetic disorders or diseases that exhibit a genetic instability, such as many cancers. Examples of single-cell investigations include capturing the genetic heterogeneity of tumours 57, 58 or comparing CTCs with the originating tumour or metastatic lesion 59 . Exome sequencing is a technique of rapidly increasing relevance to immunotherapy, as discussed further below.
Single-cell transcriptomics. Although the analysis of gene expression at the single-cell level dates back to the early 1990s 60 , the field has rapidly advanced over the past 5 years, with RNA sequencing (RNA-seq) exploiting the success of next-generation sequencing tools 61 . Indeed, RNA-seq has advanced at such a rapid pace that a new report emerges almost every month describing a new set of protocols that enable an increasingly deeper and more quantitative analysis of larger numbers of single cells 18, 39, [62] [63] [64] [65] . Applications of RNA-seq include the analysis of immune cells 64 and CTCs 66 , and capturing the transcriptional heterogeneity of various healthy 16, 67 and diseased tissues 17 . The basic biochemical method of RNA-seq is PCR, but the major technical challenges have been to engineer contamination-free methods that can account for PCR bias correction and yield absolute quantification. This goal has been best accomplished through the combined use of microfluidics platforms 63 , including microdrop technologies 68, 69 and molecular barcoding techniques 62, 69 . The microfluidics character of these approaches implies that individual cells are isolated in volumes ranging from a few tens to a few hundreds of picolitres, and this produces several advantages. First, molecular diffusion times within such small volumes are short, which can then significantly shorten the times required for chemical reactions that are part of the processes flow. Second, the small volume raises the relative concentration of the cellular analytes being investigated and lowers the copy numbers of any molecular contaminants. Finally, small volumes limit reagent costs and allow many cells to be interrogated in parallel.
Two very recent quantitative single-cell transcriptomic methods -CytoSeq and inDrop -are conceptually similar, but distinct in practice (FIG. 1) . Fan et al. 18 reported the CytoSeq technique, which utilizes dilute cell loading into 20 pl volume microwells. Each microwell contains a 20 μm magnetic bead that is functionalized with many oligo nucleotide primers, each containing a universal PCR priming site, a combinatorial cell label (the barcode), a unique molecular index (UMI) 70 and an mRNA capture sequence. All primers on each bead contain the same cell label but incorporate a diversity of molecular indices. Many mRNA molecules from a lysed cell are captured on a single bead, and all beads are combined for amplification and sequencing. Each sequence carries the barcode (single-cell identity), the molecular index (one index per transcript) and the gene identity, thus yielding a relatively deep, bias-free and quantitative analysis of the transcriptome from many single cells in parallel.
Two droplet-based microfluidics variants of this barcoding approach for single-cell transcriptomics are the DropSeq method 69 and the (simultaneously published) 
Mass cytometry
A single cell proteomics method based on traditional flow cytometry methods but uses mass labels and mass spectrometry for protein analysis.
Microengraving
A microfluidics single-cell proteomics method.
Single-cell barcode chips (SCBCs) . A single-cell proteomics method.
Single-cell western blottings (scWesterns). A microchipbased method for carrying out western blotting assays on single cells. inDrop approach 68 . The basic concept of droplet microfluidics is to use microfluidic channel designs and flow control to combine oil and water so that the water divides into sub-nanolitre volume droplets separated by oil. Each of those nanodrops can be seeded with, for example, a cell, a barcoded microbead (or equivalent) or cell lysis reagents, such that each nanodrop comprises a self-contained reaction vessel. Advanced microchip designs allow virtually the entire process, from cell introduction to delivery of reagents for sequencing, to be automated on a microchip that is approximately the size of a microscope slide. The DropSeq method was utilized for the analysis of ~45,000 single mouse retinal cells, which is a testament to the scalability of droplet microfluidics, and similar to the capabilities of the CytoSeq method.
A common concern with single-cell methods is the relationship between what is measured and the copy numbers of the analyte that were actually in the cell. Even genetically identical cells, cultured side by side, will naturally exhibit significant variations in copy numbers of transcripts, proteins, metabolites and other analytes 38, 71 
. For any analyte, capture efficiency is always an issue, and can be highly challenging to quantify. For transcriptomics, this concern is complicated by the fact that the actual mRNA transcript is not measured. Instead the mRNA transcript is a cDNA complement, amplified to many copies, that provides the input into the sequencer. Different mRNAs can be differentially amplified, and noise can be amplified along with signal 45, [72] [73] [74] . Of course, having a single-cell technique that captures the biological heterogeneity of the cells under study, rather than the measurement noise of the technique itself, is advantageous. Various methods have been used to increase and/or characterize the quantitative nature of single-cell transcriptomics 75 . The UMI 62, 70, 71 mentioned in the description of CytoSeq, which is also used by inDrop and DropSeq, is a protocol designed to limit amplification bias by associating a unique molecular signature to each mRNA copy that is captured. A related method was reported by Fu and co-workers 76, 77 . Thus, if ten copies of a specific transcript are captured from one cell, each will have the same 
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Control Drug Control Drug barcode but a different UMI; therefore, the copy numbers of a given mRNA captured is simply the number of unique UMIs for a given barcode. The use of UMIs, although a significant step towards absolute quantification, does have limitations for counting low copy number transcripts 71 . A second major issue is that of capture efficiency, which can vary from <5% 71 to ~20% 78 , and can be assessed by counting mRNA copies using UMIs relative to those recorded using fluorescence in situ hybridization 71 . Of course, a low capture efficiency will have a correspondingly large variance across many mRNAs or between different single cells, especially for low copy number transcripts. Thus, quantitating and increasing capture efficiency is an analytical frontier of the field. or mass cytometry 9 (for example, CyTOF) tools. Each of these methods rely on antibodies; therefore, in contrast to mass spectrometry proteomics of bulk samples 79, 80 , single-cell proteomics methods cannot yet serve as discovery-level tools. Among the microfluidics platforms, the microengraving technique 31, 81 , single-cell barcode chips (SCBCs) and single-cell western blottings 82 (scWesterns) provide the most advanced capabilities. Several alternative approaches, typically with reduced levels of multiplexing, have been reported, including high-throughput microdroplet-based screening approaches 29, [83] [84] [85] [86] , some of which have been reviewed elsewhere 87 . For analysis and cell sorting based on cell surface markers, flow cytometry-based fluorescent-activated cell sorting (FACS) is the mature single-cell proteomics method 4 , and interfaces with almost all other single-cell methods described in this Review. FACS is routinely used to analyse and sort viable cells based on six or more cell surface markers, and is therefore tremendously useful for purifying cellular phenotypes for subsequent analysis.
The analysis of cellular function at the molecular level, or the specific influence of drugs on that function, typically requires the analysis of functional analytes, such as phosphorylated kinases or secreted cytokines, apoptotic or proliferation markers, and/or metabolites. In general, these different classes of molecules can require different assay methods. For analysing functional cytoplasmic proteins, CyTOF is the most mature tool 11 , although SCBCs have emerged with similar and complementary capabilities 10 . ScWesterns represent the youngest technology, even though the origins of this technique can be traced back to single-cell gel electrophoresis assays, known as comet assays 88, 89 . ScWesterns are also perhaps the method that is most closely aligned to standard biology practice. Each of these tools has advantages and limitations. For analysing secreted proteins, SCBCs have the unique capability of capturing large panels (>40) of proteins secreted from viable cells 8 . Microengraving tools capture only a few secreted proteins, but permit kinetic studies of protein secretion from individual cells 90 . For both SCBCs and microengraving, cells that exhibit unique or desirable protein signatures may be further analysed 30 . CyTOF can capture large panels of 'secrete-able' proteins, but protein Box 1 | The biophysical interpretation of single-cell data The ability to quantitate the level of analytes from single cells provides fundamentally new insight into cellular biology. For example, the abundance distribution of an analyte, as tabulated across many single cells, is also called the fluctuations of that analyte, and represents a unique single-cell measurement. A certain width of the fluctuations is fundamental and unavoidable, and is reflective of the statistics associated with the many steps through which signals are processed by gene and protein networks. For purely stochastic 96 processes, the distribution width should narrow as the square root of the average copy numbers per cell of the analyte increases 162 . However, most analytes will not behave according to this limit and, in fact, the shapes of analyte distributions can reveal new biology, such as evidence of bistable steady states 163 , evidence that the cells are in a stable steady state 38 or are unstable and responding to a perturbation (for example, a drug). A relevant example of bistability might be a cell population that is composed of both a quiescent state and an active state 164, 165 , and thus yields differential responses to drugging. Measurements of multiple analytes from the same single cells can be used to extract quantitative analyte-analyte correlations (and anti-correlations). Again, this is a unique single-cell measurement. Consider, for example, the levels of the three hypothetical phosphoproteins (p-A, p-B and p-C) shown in the figure. These proteins represent a small signalling network within a cell. Stimulation (or drugging) of the cell may collectively repress these phosphoprotein levels, as is reflected in the bulk immunoprecipitation assays. However, a more in-depth picture of the signalling is revealed by an analysis of a statistical number of single cells, such as is presented in the two-dimensional scatter plots. Note that in the plots for the undrugged cells, all phosphoprotein levels are high, but only p-A and p-B are strongly correlated. On drugging, all phosphoproteins are repressed, but p-A and p-B are non-correlated, p-C and p-B are strongly correlated, and p-A and p-C are anti-correlated. This inferred correlation network is shown in the figure, in which the protein levels are indicated by the sizes of the spheres and the correlations are indicated by the edges. Correlation, of course, does not mean causation, but a correlation network generated at the single-cell level can provide a rich set of testable hypotheses that may ultimately allow the chemical kinetic relationships that comprise a signalling network to be extracted. In principle, if one knows these relationships, then one can make accurate predictions regarding how a specific drug will disrupt the cellular signalling machinery. Improved measurement quantification provides significant additional value. This is because most signalling cascades actually behave as excitable devices with built-in excitability thresholds, enabling them to integrate diverse temporal and spatial inputs to produce specific signalling responses 166 . In other words, the outputs of a signalling cascade are not typically linearly dependent on the inputs, and quantitative assays permit such input-output relationships to be more accurately defined. secretion must be blocked and the cells fixed before analysis. Consequently, the detected proteins are not actually secreted and the cells cannot be further analysed 9 . For the microfluidics tools, the cells can be imaged in situ and factors such as cell motility or morphology can be correlated with the secretion of specific proteins 91 . The microfluidics tools also permit assays on discrete numbers of cells 24, 40, 92 . As CyTOF utilizes antibody staining of fixed cells, staining can be performed within fixed tissues, thus permitting CyTOF to be used as a powerful variant of immunohistochemical staining 35 . Each of these tools requires significant user skill, although that requirement is likely to diminish as the platforms mature.
Similar to transcriptomic methods, quantitative assessment of single-cell protein levels is an increasingly important issue. All single-cell proteomics methods utilize antibodies as the dominant detection technology. A recent publication provided a protocol for establishing a clear, quantitative metric for antibody performance 93 and raised serious questions regarding whether a given antibody even detects its intended target. Of the 1,124 antibodies tested, only 452 recognized their target in HEK293 cell lysates 88 . Given that large caveat, the use of antibodies for staining (as with flow cytometry or CyTOF methods) is markedly different from their use in western blotting or fluorescent sandwich immunoassays (SCBCs and microengraving), with each affording different quality checks. scWesterns, similar to standard immunoprecipitation western blotting methods, provide two separate measurements of each protein: the mass ladder (albeit of lower resolution than is typical for bulk western blotting assays) plus a primary detection antibody 94 . However, absolute quantification and absolute assessments of experimental uncertainty can be challenging. For multiplex fluorescent sandwich immunoassays, each individual protein assay provides two separate measurements per cell (as two antibodies per protein are used). Each individual assay can also be compared against every other assay in the panel for crossreactivity 95 , and each assay can be calibrated against solutions spiked with recombinant standards 10, 95 , thus providing assay readouts in terms of copy numbers per cell. However, on a cautionary note, recombinant standards may not be commercially available or may be modified from the corresponding protein produced within the cells. SCBC platforms have an additional quality check in that individual protein levels can be assayed multiple times from the same single cell 10 , thus providing a metric for experimental accuracy. Single-cell methods that rely on antibody staining of cells are the most challenging to quantitate, although experiments on FACS-sorted cells can provide validation that the antibodies used for staining surface markers are effective, thus providing a level of quantification regarding the cell fractions that are positive or negative for specific markers.
Applications of single-cell analysis
With the development of tools that can analyse larger numbers of single cells with an increasing depth of analysis, a central emergent theme is that cellular biology is highly heterogeneous at virtually all molecular levels beyond the genome. Some of this heterogeneity is intrinsic to the nature of single cells
, although some of it is reflective of genetic or epigenetic influences 96, 97 . In many cases, it is becoming apparent that such heterogeneity is not arbitrary, and may be mined to yield new biological information. A second emergent theme is that a few cells can bias a population average 98, 99 . Single-cell genomic or transcriptomic analysis can permit lineage tracing of rare cell types (see below), which can provide insight into the origin (for example, primary tumour or metastatic site) of CTCs, or into the use of CTCs as a liquid biopsy that reflects the originating lesion 49, 59, 100, 101 . A second application, pioneered by Quake and colleagues, has been to provide a deep, molecular view of healthy 16 or diseased 102 tissue development via lineage tracing at the transcript and protein level. Related work has focused on identifying how multiple genetic defects associated with a single gene, but non-uniformly distributed throughout the tumour, influence tumour development and drug response 50 . Advances in single-cell proteomics have largely exploited the ability to interrogate combinations of secreted (or secrete-able) cytokines, chemokines and cytotoxic granules from highly defined cells of the haematopoietic lineage 103, 104 . These advances have permitted comparisons of the importance of immune cell function versus immune cell abundance 7, 9, 90, 95 (see below), and also revealed deeper insight into the haematopoietic lineage. Such studies are being applied in cancer immunotherapies 25, 53, 99, 105 , as discussed later. Single-cell proteomics has also provided detailed characterizations of the structure of phosphoprotein signalling pathways 10, 11 (see below and BOX 1) .
An emerging frontier is the use of microfluidics platforms that permit highly customized assays designed to correlate weak perturbations to single cells with changes in the transcriptome or proteome 38 . Two examples are studies that correlated cell motility with proteomic 87 or transcriptome analysis 28 . A third example is an analysis of how specific cancer cells respond to targeted inhibitors as the physical environment is altered from normoxia to hypoxia 27 . Other examples include studies of cellular responses to engineered molecular stimulations (that is, periodic versus continuous) 106, 107 , or studies designed to interrogate how one cell is influenced by another 108 , including how that influence depends on cell-cell separation distance 24, 40 . Such studies are enabled by the standardization of the relevant single-cell assay biochemistries, and are limited only by the imagination of the researchers. Together, such research represents tremendously powerful approaches for decoding how genetic and epigenetic influences (such as drugs) are processed by living organisms.
Lineage tracing of cellular phenotypes. Single-cell proteomics and transcriptomics can be used to understand the origins of cellular heterogeneity, as demonstrated by Dalerba and co-workers in colon cancer 102 (FIG. 3) . It was found that the transcriptional diversity of a human tumour could be largely explained by in vivo multilineage differentiation 102 . These findings are consistent with additional models 109 and mechanistic 110 investigations that demonstrate the ability of cancer cell differentiation (and de-differentiation) to maintain a phenotypic equilibrium within certain tumours. The study by Dalerba and colleagues 102 was limited by the numbers of transcripts per cell, and the numbers of single cells, that could be analysed a few years ago. The recent advent of high-throughput, single-cell global transcriptome analysis and exome sequencing should allow for such lineage tracing studies to dive significantly deeper into a host of developmental biology problems with relevance to both healthy and diseased states.
Understanding cellular functionality.
Immune cells of the myeloid lineage are often considered the first responders of host defence against bacterial infection, whereas haematopoietic stem and progenitor cells (HSPCs) are thought to respond in a delayed manner to ensure the sufficient production of myeloid cells, which are consumed during an infection [111] [112] [113] . This response of HSPCs was considered to be a passive response to the depletion of downstream immune cells. However, recent evidence suggests that HSPCs may participate directly by sensing systemically elevated cytokines as well as bacterial and viral components through cytokine receptors and Toll-like receptors, respectively 114, 115 . Single-cell functional proteomics (12-plex SCBC assays), combined with flow cytometry cell sorting and genetically engineered mouse models, indicated that short-term haematopoietic stem cells (HSCs) and multipotent progenitor cells also have the capacity to respond to bacterial components via the Toll-like receptor-nuclear factor-κB axis 103 . In fact, HSPCs were significantly more potent cytokine producers in terms of speed, breadth and especially quantity than the conventional cytokine producers of the immune system, such as myeloid cells and lymphocytes 95 . Clustering of data from HSC SCBC assays revealed four functional subsets of LKS HSCs (defined as Lineage -Sca1 + cKit + ); these cells secreted a set of lymphoid cytokines, a set of myeloid-associated cytokines, produced all proteins or were completely silent 95 . The overall findings indicated that short-term HSCs and multipotent progenitor cells, although rare cells, can aggressively translate danger signals arising from an infection into the vigorous production of cytokine signals that allow them to directly self-regulate stress-induced haematopoiesis. These findings have multiple implications, with one possibility being related to patients who have undergone lymphodepletion regimens as part of a therapeutic procedure. As the single-cell functional proteomics assays are non-destructive to the cells, a logical next step in this type of work would be to analyse those functional subsets at the transcriptome level to identify whether there are specific cell surface markers that can be used to further differentiate these HSPC functional subsets.
High-throughput drug screening. Although single-cell methods can provide valuable information, most are limited to analysing only one to a few samples at a time. However, cellular barcoding techniques are evolving to remove this limitation 18, 116 . For mass cytometry, the basic idea is that cells are separated into a multiwell plate and barcoded with a unique combination of mass signatures that identify a given cell with its well location and the experimental conditions (that is, a specific dose of a specific drug) applied to that location. The cells are then analysed simultaneously to enable the parallel capture of many experimental conditions. For example, Bodenmiller and co-workers 116 used 7 mass-labelled barcodes to provide up to 2 7 barcoding capacity (128 possible addresses). This method was applied to a 96-well plate format to explore the kinetic and/or dosing influences of 27 inhibitors on 14 distinct peripheral blood mononuclear cell phenotypes (defined by 10 cell surface markers) via the monitoring of 14 phosphorylation sites per cell. From these data, half-maximal inhibitory concentration (IC 50 ) values and percentage inhibition of the phosphorylation levels for all phosphorylated sites were extracted 116 .
As described above, single-cell, multiplex phosphoproteomic assays yield both the levels of the assayed proteins and the protein-protein correlations. Thus, a major advantage and distinguishing feature of this high-throughput screening approach is that it permits an analysis of how both on-target and off-target drug interactions influence the signalling networks, rather than just the relevant protein levels. A major challenge going forward will be to expand the multiplexing of these types of assays to capture more complete pictures of the phosphoprotein signalling networks, as well as additional networks associated with cellular proliferation, apoptosis and metabolism.
Single-cell analysis in oncology
The single-cell analytical methods discussed in this Review are being applied towards addressing several fundamental biomedical problems, particularly in cancer biology and clinical oncology. Below, we discuss how single-cell analysis is being applied to two key areas of cancer research and drug discovery: cancer immunotherapy and tumour heterogeneity.
Cancer immunotherapy. The prototype model for our understanding of cellular differentiation and diversification in humans is the haematopoietic system. In fact, this knowledge has provided a scientific cornerstone under lying the recent and remarkable advances in cancer immunotherapy 117, 118 . Single-cell technologies have emerged as a critical set of tools for advancing this knowledge, often in a dramatic manner.
For cancer immunotherapies, single-cell analytical tools are beginning to provide critical guidance across multiple levels of biological information. Whether the immunotherapy is based on dendritic cell vaccines 119 , adoptive cell transfer 120 or checkpoint inhibitors [121] [122] [123] , or some combination thereof, the primary tumour cell killers are T cells. Some of the most important biomarkers are the kinetic persistence and functional behaviours of specific antitumour T cell phenotypes across the course of a given patient's therapeutic regimen. For cell-based therapies, the importance of designing clinical protocols that account for T cell differentiation has emerged as a key consideration 124 . In addition, a few years ago it was suggested that patient-specific mutant epitopes 125 (called neoantigens) may be a potentially important factor for understanding, or perhaps controlling, the antitumour specificity of an immunotherapy; this theory has recently been confirmed 105, [126] [127] [128] [129] [130] . Closely associated factors are the TCRα and TCRβ chain sequences that recognize the specific expressed neoantigens with high avidity 53 . Much of this work has involved highly multiplex flow and mass cytometry methods 7, 9, 131, 132 and associated reagent development [133] [134] [135] [136] [137] [138] . These techniques enable the phenotypic characterization of immune cells and also the study of intracellular signalling pathways. With the realization that T cell responses to cancer can lead to unprecedented levels of durable tumour responses in several types of cancer (for example, melanoma, lung, bladder, lymphoma, leukaemia) 139 , there is a need for further characterization of such responses to facilitate the increased refinement of therapeutic approaches and continued improvements in patient care.
To understand immune responses to cancer, it is of significant interest to develop approaches that can match the TCR genes with their specific (or cognate) antigen, which usually result from nonsynonymous somatic mutations specific for each cancer 105, 133, [135] [136] [137] [138] 140, 141 . As each T cell has two TCR chains, it is important that they are defined from individual T cells to allow their correct pairing. Single-cell analysis platforms coupled with DNA sequencing for TCR chains and paired neoantigens have the potential to revolutionize our knowledge about this critical interaction, guiding the success of cancer immunotherapy strategies 17, 53 . With the increased knowledge, it is easy to envision that in the near future the definition of TCR chains that specifically recognize neoantigens in cancers may be translated into truly personalized cancer immunotherapy approaches for patients.
Once the recognition elements of T cells are fully defined, a next question is which T cell subsets are empowered to fight cancer. Although these T cell subsets are each governed by specific transcription factors and can be identified by a series of surface molecules 142 , a specific subset can also exhibit a broad range of functional phenotypes, ranging from antitumour to immunomodulatory 99 . Singlecell assays provide an unparalleled quantitative assessment of the different T cell subtypes, their progenitors and their functional capabilities 9, 12, 37, 99, 103 . These assays are being applied to the characterization of T cell responses to cancer induced by several immunotherapy approaches 99, 103 . Such methods are helping to define how patients respond to or resist immunotherapy approaches, such as checkpoint blockade therapy, and may help guide the next generation of combination therapy studies that will be designed based on understanding what is lacking in patients whose immune systems do not respond to these therapies.
Advances in cell therapy manufacturing for adoptive cell transfer approaches, in which a large army of T cells are manufactured in the laboratory and re-infused back into patients, are being supported by new biotechnology approaches designed to guide higher level T cell characterizations 25, 53, 105, 130 . The understanding of TCR specificity and the generation of chimeric antigen receptors to genetically redirect T cell specificity to cancer enables the manufacture of autologous cell therapies 143 . By applying highly multiplexed single-cell analyses, the different T cell subsets can be surveyed before and after infusion of these cell therapies to patients to define which approaches improve their long-term functionality to attack cancer. It has become clear that less mature cells that have longterm repopulation ability (for example, naive, T stem cell and long-term memory cells) are preferred in these adoptive cell transfer approaches 124 ; more mature T effector cells have short-term functionality and cancer may regrow after their infusion 99, 144 . The next wave of advances in cancer immunotherapy are likely to rely on the characterization of large numbers of single immune cells at the DNA, RNA and protein levels to deconvolute the complexity of immune responses to cancer and guide further therapeutic strategies. Lower order analyses fail to provide the necessary knowledge to understand immune responses to cancer and cannot explain the heterogeneity in patient responses.
Understanding tumour heterogeneity. Intratumoural heterogeneity is increasingly being recognized as a central hallmark of human cancer 145 , and encompasses three main types of variability: variations in mutational patterns among tumours of the same histological type; variations in histological patterns within a tumour; and intratumoural mutational polyclonality, that is, variations in the mutational complement within individual cells of a tumour 146 . In addition to mutational polyclonality, single cells within a tumour will intrinsically vary in the activity of their signalling 10, 11 and metabolic 23 networks, thus influencing the biological properties and therapeutic vulnerabilities of distinct tumour cell subpopulations. Due to a lack of suitable genetic tools, the impact of intratumoural mutational polyclonality and heterogeneity of signalling and biochemical networks on treatment and resistance are not currently well understood.
Tumours develop into a complex heterogeneous tumour mass, primarily through the intertwined forces of spontaneous somatic mutation coupled to clonal sequential selection for aggressive subclones 145, [147] [148] [149] . As tumours progress, new mutations are produced with an ever increasing frequency, accelerating the extent of intratumoural mutational polyclonality and confounding treatment strategies 146, 147 . Intratumoural mutational polyclonality is enhanced in cancers that are associated with a causal environmental insult that directly damages DNA 150 , as well as by the progressive loss of key tumour suppressor proteins, and mutations in genes that sense and repair damaged DNA 151 . The local microenvironment also provides a critical non-genetic force. Autocrine and paracrine interactions among inflammatory, stromal, endothelial and tumour cells are just a few factors that can influence the process of selection, and may yield cells bearing different mutations within different parts of a tumour or its distant metastases 152, 153 . Treatments also provide a source of non-genetic heterogeneity, expanding or collapsing tumour cell subpopulations depending on the treatment 145, 146, 149 . Exome and genome-wide surveys have provided an atlas of driver mutations and a compelling road map for guiding the implementation of precision and personalized cancer medicine. However, intratumoural heterogeneity presents a serious challenge to this paradigm 154 . Fortunately, single-cell technologies are poised to address this challenge.
Glioblastoma, the most common and lethal form of primary brain cancer, provides an illustrative example. Glioblastoma was one of the first cancers sequenced by The Cancer Genome Atlas 155, 156 . In that survey, 57% of tumours contained epidermal growth factor (EGFR) amplification and/or gain-of-function mutations, including EGFR variant III (EGFRvIII) 157, 158 . EGFRvIII is oncogenic in mouse models when introduced in association with cyclin-dependent kinase inhibitor 2 (CDKN2A) loss 159 ; a combination that commonly occurs in patients 146 . However, EGFRvIII protein expression varies dramatically among cells within a glioblastoma, and single-cell DNA sequencing 50 , RNA sequencing 17 , as well as bulk analysis of DNA and RNA extracted from different regions of a tumour 160, 161 demonstrate considerable DNA, transcript and protein heterogeneity, including of EGFRvIII. Importantly, recent research suggests that the widespread variability of gene, transcript and protein levels of EGFRvIII within individual cells of a glioblastoma may contribute to the resistance to EGFR-targeted therapies that is currently seen in the clinic 110 . In addition, single-cell barcode proteomics and metabolomics assays point to considerable variability in the signalling and metabolic networks of individual glioblastoma cells 23 within an EGFRvIII + tumour, potentially shedding new light on mechanisms of resistance (either pre-existing and/or adaptive) to targeted therapies that could be used to guide more effective combination treatments.
Challenges, limitations and outlook
The emergence of single-cell omics tools over the past 5 years has happened at a lightning pace, and the potential for their use in the discovery and development of broad classes of therapies and therapeutic strategies is high. The resultant datasets do not simply provide deeper views of biology that are already measured using existing methods, but also provide a fundamentally different view that is not masked by the intrinsic heterogeneity of a cell population. However, the novelty of these single-cell techniques also implies various limitations. For example, most methods discussed in this Review have just recently emerged from academic laboratories and therefore require significant skill sets and cross-disciplinary infrastructure that may be new to those in the drug discovery and development community. As cases in point, REFS. 102,103,116 (discussed above) have, on average, 13 authors representing 5 different departments or institutions, which demonstrate the need to effectively integrate experts in technology, biology and computational analysis. A second caveat is that algorithms for the in-depth analysis of single-cell data are even less mature than the experimental platforms, and effective visualization and interpretation of what are increasingly large datasets remain challenging, with techniques that vary across research groups. However, as methods mature, the experimental protocols, the reagents and the computational analysis routines will become more standardized. This standardization has, of course, largely occurred for multicolour flow cytometry, and it is beginning to happen for CyTOF and single-cell RNA-seq, but even these methods are rapidly evolving and all involve dedicated user facilities.
Much of modern biological practice is designed around extracting correlations and associated statistical trends from biological systems that are intrinsically heterogeneous and therefore noisy. The promise of single-cell biology is to resolve and make sense of this confounding heterogeneity. Several studies highlighted in this Review provide hints of the resultant clarity that can be achieved. It is likely that, as the tools of the field increase in terms of quantification, throughput and ease of use, the impact will be to fundamentally change the practice of biology, as well as the associated applied sciences, including drug discovery and development.
